Search

Canine mammary tumors (CMT) are the second most common form of neoplasia accounting for 40% of tumors in dogs. Today, as we know cancer is a disease of multiple genes and molecules. Research across the last three decades has enhanced our understanding of these molecules which is making possible new strategies of predicting, diagnosing and clinical treatment of this malady. Biomarkers are the modern day “neoplastic signatures” which enhances the specificity of tumor diagnosis allowing the researchers to differentiate tumors at the molecular level. This review enlists a concise summary of novel serum biomarkers counting matrix metalloproteinases, lysyl oxidase, heat shock proteins, mammaglobin, kynurenine 3-monooxygenase, WT1, nectin 4, and ERBB2. These new-fangled markers of canine malignancy could might help in early and accurate diagnosis resulting in more effective treatment and better prognosis. Nevertheless, more detailed research of these biomarkers along with their role in other cancers should be further validated in future.

The new series of 1-(4,5-dihydro-5-phenyl-3-diphenylpyrazol-1-yl)butan-1-one derivatives were synthesized by cyclization method using biphenyl chalcone with n-butyric acid and hydrazine hydrate. The synthesized 1-(4,5-dihydro-5-phenyl-3-diphenylpyrazol-1-yl)butan-1-one derivatives chemical structures were confirmed from spectral data such as FT-IR, 1H and 13C NMR. 2-Pyrazoline derivatives were docked with bacterial (1UAG) and breast cancer (1OQA) protein. Based on high binding affinity score, the best compound was subjected to in vitro anticancer activity by MTT assay. Also, antimicrobial activity were studied for synthesized 2-pyrazoline derivatives.

A study was conducted to assess the thyroid hormones and lipid profile in Labrador Retriever male dogs presented to the Veterinary College Hospital, Bengaluru for routine health check up and vaccination. Based on their age, they were randomly divided into Group I, Group II and Group III that consisted of one to three years age (young age), more than three years to six years age (middle age) and more than six to nine years age (old age), respectively. In all the dogs the body weight was recorded. The profile of thyroid hormones such as thyroid stimulating hormone (TSH), triiodothyronine (T3) and Thyroxine (T4) were estimated by using ELISA kits. The lipid profile parameters such as triglycerides, cholesterol and HDL cholesterol were estimated by using biochemical reagent kits. The values of LDL and VLDL cholesterol were calculated by using Friedewald formula. Further, the blood glucose level was estimated using the Glucochek® glucometer and serum total protein level by using reagent kit. Results revealed that the increased body weight was observed as age advanced. The T3 levels did not vary significantly among different age groups. Whereas, in the advanced age groups there was reduction in T4 levels and increase in TSH levels which was suggestive of hypothyroidism. Triglycerides, cholesterol, LDL and VLDL levels were significantly higher in older dogs followed by middle age group compared to young age group. However, the alterations in blood glucose and serum total protein levels were non significant between different age groups. It was concluded that the Labrador Retriever male dogs could be more prone to hypothyroidism and hyperlipidemia and therefore master health check-up could be taken up at least once in a year as a precautionary measure to avoid complications of hypothyroidism and hyperlipidemia.